经典上皮状态驱动胰腺癌对KRAS抑制的急性耐药
胰腺导管腺癌(PDAC)存在基底与经典上皮癌细胞状态的平衡。利用基因工程小鼠模型和患者来源异种移植,研究发现基底PDAC细胞对KRAS抑制剂高度敏感;荧光和生物发光报告系统纵向追踪显示KRAS抑制剂诱导经典状态快速富集,谱系追踪表明这些富集的经典PDAC细胞是疾病复发的储库;遗传或化疗介导清除经典细胞状态与KRAS抑制协同。
要点
- 基底PDAC细胞对KRAS抑制剂高度敏感。
- KRAS抑制剂诱导经典上皮状态快速富集,成为复发储库。
- 清除经典细胞状态与KRAS抑制协同,为临床前概念验证。
核心结论
- 经典上皮癌细胞状态对KRAS抑制急性耐药,并作为疾病复发的储库。
- 靶向经典状态联合KRAS抑制可加深缓解,揭示潜在治疗策略。
- 研究结果支持将经典状态导向治疗与KRAS抑制剂联合以加深缓解并对抗耐药。
研究设计与样本
- 使用基因工程小鼠模型和患者来源异种移植。
- 采用荧光和生物发光报告系统在体内纵向追踪细胞状态动态。
- 通过谱系追踪识别富集的经典PDAC细胞来源。
- 通过遗传或化疗介导清除经典细胞状态并与KRAS抑制联合评估协同作用。
主要发现
- 基底PDAC细胞对KRAS抑制剂高度敏感。
- KRAS抑制剂诱导经典状态快速富集。
- 富集的经典PDAC细胞是疾病复发的储库。
- 遗传或化疗介导清除经典细胞状态与KRAS抑制协同。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intratumoral heterogeneity in pancreatic ductal adenocarcinoma (PDAC) is characterized by a balance between basal and classical epithelial cancer cell states, with basal dominance associating with chemoresistance and a dismal prognosis. Targeting oncogenic KRAS, the primary driver of pancreatic cancer, shows early promise in clinical trials, but efficacy is limited by acquired resistance. Using genetically engineered mouse models and patient-derived xenografts, we find that basal PDAC cells are highly sensitive to KRAS inhibitors. Employing fluorescent and bioluminescent reporter systems, we longitudinally track cell-state dynamics in vivo and reveal a rapid, KRAS inhibitor-induced enrichment of the classical state. Lineage tracing uncovers that these enriched classical PDAC cells are a reservoir for disease relapse. Genetic or chemotherapy-mediated ablation of the classical cell state is synergistic with KRAS inhibition, providing a preclinical proof of concept for this therapeutic strategy. Our findings motivate combining classical state-directed therapies with KRAS inhibitors to deepen responses and counteract resistance in pancreatic cancer. Significance: KRAS inhibitors hold promise in pancreatic cancer, but responses are limited by acquired resistance. We find that a classical epithelial cancer cell state is acutely resistant to KRAS inhibition and serves as a reservoir for disease relapse. Targeting the classical state alongside KRAS inhibition deepens responses, revealing a potent therapeutic strategy. See related commentary by Marasco and Misale, p. 2018.
引用
- Singhal A, Styers HC, Rub J, et al. A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer. Cancer Discov. 2024. PMID: 38975873. doi:10.1158/2159-8290.CD-24-0740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。